- Home
- NA vs XFOR Comparison
NA vs XFOR Comparison
Compare NA & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- XFOR
- Stock Information
- Founded
- NA 2019
- XFOR 2014
- Country
- NA China
- XFOR United States
- Employees
- NA N/A
- XFOR N/A
- Industry
- NA Semiconductors
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NA Technology
- XFOR Health Care
- Exchange
- NA Nasdaq
- XFOR Nasdaq
- Market Cap
- NA 95.7M
- XFOR 84.3M
- IPO Year
- NA 2022
- XFOR N/A
- Fundamental
- Price
- NA $5.07
- XFOR $3.05
- Analyst Decision
- NA
- XFOR Strong Buy
- Analyst Count
- NA 0
- XFOR 3
- Target Price
- NA N/A
- XFOR $34.17
- AVG Volume (30 Days)
- NA 217.2K
- XFOR 1.0M
- Earning Date
- NA 08-15-2025
- XFOR 11-12-2025
- Dividend Yield
- NA N/A
- XFOR N/A
- EPS Growth
- NA N/A
- XFOR N/A
- EPS
- NA N/A
- XFOR N/A
- Revenue
- NA $3,369,693.00
- XFOR $32,774,000.00
- Revenue This Year
- NA N/A
- XFOR $1,313.84
- Revenue Next Year
- NA N/A
- XFOR N/A
- P/E Ratio
- NA N/A
- XFOR N/A
- Revenue Growth
- NA N/A
- XFOR 5721.31
- 52 Week Low
- NA $2.77
- XFOR $1.35
- 52 Week High
- NA $31.48
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- NA 47.10
- XFOR 48.72
- Support Level
- NA $4.82
- XFOR $2.88
- Resistance Level
- NA $5.20
- XFOR $3.37
- Average True Range (ATR)
- NA 0.37
- XFOR 0.36
- MACD
- NA 0.05
- XFOR -0.12
- Stochastic Oscillator
- NA 25.75
- XFOR 14.05
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.